Use of an Amphoteric Solution in Eye, Skin and Oral Chemical Exposures: Retrospective Multicenter Clinical Case Series

Fortin JL, Fontaine M, Bodson L, Depil-Duvala A, Bitar MP, Macher J, Paulin P, Ravat F and Hall AH

1Emergency Department, Belfort Montbéliard Hospital, 14 Mulhouse Street, 90 000 Belfort, France
2Preventive Medicine, 82 Bergson Street, 42 000 Saint-Etienne, France
3Medical Department, Sdtis 25, 10 Clairière Street, 25 042, Besançon Cedex, France
4Burn Intensive Care Unit, Saint Joseph Saint Luc Hospital, 20 Quai Claude Bernard, 69007 Lyon, France
5Emergency Department, University Hospital, Sart Tilman B, 4000 Liege, Belgium
6Emergency Department, St-Luc-St-Joseph Hospital, 20 Quai Claude Bernard, 69 007 Lyon, France
7Emergency Department, Nouvel Hôpital Street 26, 88100 Saint-Dié-des-Voges, France
8Toxicology Consulting and Medical Translating Services, P.O. Box 1255, Azle, Texas 76098, USA
9Colorado School of Public Health, University of Colorado-Denver, Denver, Colorado, USA

*Corresponding author: Alan H Hall, Medical Toxicologist, Toxicology Consulting and Medical Translating Services, P.O. Box 1255, Azle, TX 76098-1255, USA, Tel: 1-307-399-1564; E-mail: OldEDDoc@gmail.com

Received date: February 22, 2017; Accepted date: March 21, 2017; Published date: March 27, 2017

Copyright: © 2017 Fortin JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: A polyvalent amphoteric flushing solution (Diphoterine®) has been in use for a number of years, mainly in industrial settings for decontamination of acid, base, and other corrosive or irritant substances eye and skin splashes.

Methods: Retrospective collection of 34 cases from several centers reporting use of Diphoterine® decontamination of eye, skin or oral chemical exposures. The following data were retrieved: exposure circumstances (workplace, domestic, deliberate assault), chemical nature and pH, exposure type, initial clinical signs, clinical signs after flushing, initial and final visual analog scale (VAS) pain ratings, consulting specialist physicians’ conclusions.

Results: 58.8% of the 34 cases were occupational exposures, 29.4% were domestic, 5.9% occurred in schools, and 5.9% were deliberate chemical assaults. Of involved chemicals, 11 were basic substances, 11 were acidic, 1 was an oxidizing substance, 2 were solvents, and 9 were miscellaneous substances. There were 21 ocular exposures, 8 cutaneous exposures, 4 mixed (ocular/cutaneous), and 1 oral exposure. Initial clinical findings in ocular exposures were: pain, blepharospasm, hyperemia, palpebral edema, and blurred vision. Of cutaneous exposures, 1 was a deep necrotic injury and 7 were superficial. Median (IQR) VAS before flushing with Diphoterine® was 7; VAS after ocular or skin flushing was 1.

Conclusion: Early application of the amphoteric solution to the eye or skin reduces the intensity of pain associated with chemical injury. While randomized clinical trials are lacking, early use of the amphoteric solution appears to reduce the incidence of sequelae.

Keywords: Diphoterine®; Amphoteric solution; Eye decontamination; Skin decontamination; Oral decontamination; Chemical burns; Chemical injuries

Introduction

A polyvalent amphoteric flushing fluid (Diphoterine® solution) has been utilized for a number of years for decontamination of eye and skin chemical splashes, mainly in industrial settings. Application of this flushing fluid as soon as possible after the chemical splash at the accident site can prevent or limit the consequences.

Recently, a number of emergency departments have begun using this amphoteric flushing fluid in either the pre-hospital or hospital settings (use by the mobile emergency and intensive care services (SMUR) or in accident and emergency departments). In these circumstances, use of this solution may be more delayed than in industrial settings.

Methods

A retrospective multicenter case series of patients with chemical splash exposures decontaminated with Diphoterine® was assembled from the following hospital emergency departments and pre-hospital services for the years 2013 to 2016:

- Emergency Department, Belfort Hospital (France)
- Emergency Department, Montbéliard Hospital (France)
- Emergency Department, Evreux Hospital (France)
Thirty-four patients with chemical splash exposures presenting to the above emergency services were included. The following data were retrieved from each patient’s medical records and recorded: age, gender, exposure circumstances, chemical nature and pH, type of exposure, initial clinical symptoms and signs, clinical symptoms and signs after Diphoterine® decontamination, pain assessment before, during, and after Diphoterine® flushing using a Visual Analog Scale (VAS; 0-10), time interval between exposure and beginning flushing, and consulting specialists’ conclusions.

The Wilcoxon Rank Sum Test was utilized to compare the VAS pain level before and after Diphoterine® with p<0.05 considered statistically significant.

The amphoteric flushing solution (Diphoterine®) was used in compliance with the following protocols:

For Eye Splashes:
- Use of a 500 mL container of Diphoterine® solution;
- A rapid and initial VAS pain assessment was conducted before flushing of each involved eye with 500 mL of Diphoterine® solution;
- VAS pain intensity was assessed during and after flushing;
- Afterwards, rinsing with 500 mL of normal saline was done to prevent dry-eye syndrome because of the hypertonicity of Diphoterine® solution;
- Then, consultation with an ophthalmologist. (See Figure 1: Protocol for use in the event of eye splashes)

For Skin Splashes:
- Use of a 200 mL container of Diphoterine® solution;
- A 200 mL Diphoterine® container enables decontamination of ~9% of the Total Body Surface Area (TBSA) of an adult patient;
- A rapid initial assessment of the VAS pain level was done before flushing.
- At the conclusion of flushing, the VAS pain level was again assessed;
- Then, a burn specialist’s opinion was obtained. (See Figure 2: Protocol for use in the event of skin splashes.)

Results

Thirty-four patients were included in the retrospective study. Details of each case described by exposure circumstances (isolated eye lesions, isolated skin lesions, mixed eye and skin lesions, oral lesions) are shown in Tables 1a-1d. The median age of the patients was 37 years (IQR 25–45) and the male/female gender ratio was 61.30/38.70.
<table>
<thead>
<tr>
<th>Clinical cases</th>
<th>Eye lesion</th>
<th>Chemical pH</th>
<th>Interval between splash and washing</th>
<th>Initial clinical signs</th>
<th>Initial VAS</th>
<th>Clinical signs post-washing</th>
<th>Final VAS</th>
<th>Specialist opinion</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.1</td>
<td>Bilateral lesions</td>
<td>Euphorbia lathyris latex pH=9</td>
<td>310 min</td>
<td>Blepharospasm Eye pain Palpebral edema</td>
<td>10</td>
<td>Decrease of pain and blepharospasm</td>
<td>3</td>
<td>Moderate conjunctival lesion</td>
</tr>
<tr>
<td>No.2</td>
<td>Bilateral lesions</td>
<td>Tear gas agent</td>
<td>30 min</td>
<td>Ocular hyperemia Eye pain</td>
<td>10</td>
<td>Resolution of hyperemia and pain</td>
<td>0</td>
<td>No conjunctival lesion</td>
</tr>
<tr>
<td>No.3</td>
<td>Unilateral lesion</td>
<td>Acrylic coating</td>
<td>20 min</td>
<td>Ocular hyperemia Eye pain</td>
<td>6</td>
<td>Resolution of hyperemia Disparition of pain</td>
<td>0</td>
<td>No conjunctival lesion</td>
</tr>
<tr>
<td>No.9</td>
<td>Bilateral lesions</td>
<td>CaOH₂</td>
<td>89 min</td>
<td>Ocular hyperemia, pain, palpebral edema, no reduction in visual acuity</td>
<td>10</td>
<td>Decrease of pain</td>
<td>3</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.10</td>
<td>Unilateral lesion</td>
<td>Mewa Bio-Circle® degreasing agent – pH=1,5</td>
<td>110 min</td>
<td>Blurred vision, left eye clouding</td>
<td>1</td>
<td>Decrease of initial symptoms</td>
<td>0</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.11</td>
<td>Unilateral lesion</td>
<td>Indal Proclean® detergent for dairy equipment cleaning pH=1,5</td>
<td></td>
<td>Hyperemia, blurred vision Eye pain</td>
<td>9</td>
<td>Disparition of initial symptoms</td>
<td>3</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.12</td>
<td>Unilateral lesion</td>
<td>Bactifoam® alkaline liquid disinfectant pH=13</td>
<td>71 min</td>
<td>Ocular hyperemia Blepharospasm Eye pain</td>
<td>6</td>
<td>Resolution of the hyperemia and blepharospasm Reduction of pain</td>
<td>1</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.13</td>
<td>Bilateral lesions</td>
<td>98% sulfuric acid pH=1</td>
<td>1 min</td>
<td>Mild eye pain</td>
<td>3</td>
<td>Resolution of pain</td>
<td>0</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.15</td>
<td>Unilateral lesion</td>
<td>Resosanit saphir® pH=1</td>
<td>55 min</td>
<td>Eye pain</td>
<td>4</td>
<td>Diminution of pain</td>
<td>2</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.16</td>
<td>Bilateral lesions</td>
<td>Caustic Soda</td>
<td>40 min</td>
<td>Ocular hyperemia Mild eye pain</td>
<td>2</td>
<td>Resolution of the hyperemia and pain</td>
<td>0</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.17</td>
<td>Unilateral lesion</td>
<td>Solvant J900®</td>
<td>1 min</td>
<td>Ocular hyperemia Eye pain</td>
<td>7</td>
<td>Diminution of pain</td>
<td>2</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.18</td>
<td>Bilateral lesions</td>
<td>Tear gas agent</td>
<td></td>
<td>Eye pain Watering</td>
<td>9</td>
<td>Diminution of pain</td>
<td>5</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.22</td>
<td>Bilateral lesions</td>
<td>Disinfectant P3-topactive®DES Peroxetic acid and hydrogen peroxide pH=3,4</td>
<td>87 min</td>
<td>Hyperemia Blurred vision Eye pain</td>
<td>5</td>
<td>Disparition of hyperemia, blurred vision and eye pain</td>
<td>1</td>
<td>No ophthalmological lesion</td>
</tr>
</tbody>
</table>
Table 1a: Presentation of the isolated eye lesions.

<table>
<thead>
<tr>
<th>No.</th>
<th>Chemicals</th>
<th>pH</th>
<th>Interval between splash and washing</th>
<th>Initial clinical signs</th>
<th>Initial VAS</th>
<th>Clinical signs post-washing</th>
<th>Final VAS</th>
<th>Specialist opinion Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.23</td>
<td>Degreaser disinfectant concentrate Atout Vert 302® pH=2.5</td>
<td></td>
<td>180 min</td>
<td>Eye pain</td>
<td>5</td>
<td>Disparition of eye pain</td>
<td>0</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.26</td>
<td>Acetone Biotech Biologique Onix®</td>
<td></td>
<td>140 min</td>
<td>Hyperemia</td>
<td>4</td>
<td>Disparition of eye pain, blurred vision and eye pain</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>No.27</td>
<td>Ammonium hydroxide, Silver Nitrate, Oxalate ammonium chloride Barium</td>
<td></td>
<td>85 min</td>
<td>Hyperemia</td>
<td>2</td>
<td>Disparition of eye pain, blurred vision and eye pain</td>
<td>0</td>
<td>No ophthalmological lesion</td>
</tr>
<tr>
<td>No.30</td>
<td>Methyl methacrylate OPTIPAC 60®</td>
<td></td>
<td>90 min</td>
<td>Hyperemia</td>
<td>4</td>
<td>Disparition of eye pain, blurred vision and eye pain</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>No.31</td>
<td>Phosphoric acid 20%</td>
<td></td>
<td>95 min</td>
<td>Hyperemia</td>
<td>8</td>
<td>Disparition of eye pain and hyperemia</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>No.32</td>
<td>Butylhydroxytoluene Stronghole®</td>
<td></td>
<td>131 min</td>
<td>Hyperemia</td>
<td>3</td>
<td>Disparition of eye pain and hyperemia</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>No.33</td>
<td>Chlorhexidine 0,2%</td>
<td></td>
<td>7 min</td>
<td>Hyperemia</td>
<td>7</td>
<td>Disparition of hyperemia and pain</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>No.34</td>
<td>Anios gel® pH=5.5</td>
<td></td>
<td>6 min</td>
<td>Hyperemia</td>
<td>6</td>
<td>Disparition of hyperemia and pain</td>
<td>1</td>
<td>Moderate conjunctival lesion</td>
</tr>
</tbody>
</table>

Acetic acid, Peracetic acid and hydrogen peroxide pH=1.6

<table>
<thead>
<tr>
<th>No.</th>
<th>Chemical (pH)</th>
<th>Interval between splash and washing</th>
<th>Initial clinical signs</th>
<th>Initial VAS</th>
<th>Clinical signs post-washing</th>
<th>Final VAS</th>
<th>Specialist opinion</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.24</td>
<td>Cement pH=13</td>
<td>360 min</td>
<td>Skin pain</td>
<td>8</td>
<td>Reduction of pain</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.25</td>
<td>Cement pH=13</td>
<td>360 min</td>
<td>Skin pain</td>
<td>7</td>
<td>Reduction of pain</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.29</td>
<td>Caustic Soda</td>
<td>45 min</td>
<td>Phlyctenae TBSA=1%</td>
<td></td>
<td>Reduction of pain</td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 1b: Presentation of the isolated skin lesions.**

<table>
<thead>
<tr>
<th>Clinical cases</th>
<th>Chemical (pH)</th>
<th>Interval between splash and washing</th>
<th>Initial clinical signs</th>
<th>Initial VAS</th>
<th>Clinical signs post-washing</th>
<th>Final VAS</th>
<th>Specialist opinion</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.5</td>
<td>Aluminum-manganese mixture</td>
<td>20 min</td>
<td>Eye pain</td>
<td>10</td>
<td>Conjunctival irritation of the right eye</td>
<td>4</td>
<td>No ophthalmological lesion</td>
<td>Superficial burns</td>
</tr>
<tr>
<td>No.6</td>
<td>98% sulfuric acid pH=1</td>
<td>5 min</td>
<td>Eye pain</td>
<td>9</td>
<td>Resolution of pain and facial erythema</td>
<td>2</td>
<td>No ophthalmological lesion</td>
<td>Superficial burns</td>
</tr>
<tr>
<td>No.7</td>
<td>25% sodium hydroxide pH=12</td>
<td>308 min</td>
<td>Facial erythema</td>
<td>8</td>
<td>Resolution of hyperemia and the facial erythema</td>
<td>2</td>
<td>No ophthalmological lesion</td>
<td>Superficial burns</td>
</tr>
<tr>
<td>No.28</td>
<td>Glyphosate de soude</td>
<td>65 min</td>
<td>Blepharospasm Facial phlyctenae</td>
<td>9</td>
<td>Resolution of blepharospasm</td>
<td>6</td>
<td>No ophthalmological lesion</td>
<td>Superficial burns</td>
</tr>
</tbody>
</table>

**Table 1c: Presentation of the mixed lesions (skin and eyes).**

<table>
<thead>
<tr>
<th>Clinical cases</th>
<th>Chemical (pH)</th>
<th>Interval between splash and washing</th>
<th>Initial clinical signs</th>
<th>Initial VAS</th>
<th>Clinical signs post-washing</th>
<th>Final VAS</th>
<th>Specialist opinion</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.21</td>
<td>Ammoniac</td>
<td>555 min</td>
<td>Buccal and lingual burns</td>
<td>3</td>
<td>Decrease lingual burn</td>
<td>1</td>
<td>No taste loss</td>
<td>No burn after 48 hours</td>
</tr>
</tbody>
</table>

**Table 1d: Presentation of the Oral lesions.**

In 58.8% of cases, the chemical exposure occurred in an industrial setting. In 29.4%, exposure was in a domestic setting, and in 5.9% of cases exposure occurred in an educational setting. In 5.9% of cases, the chemical exposure was due to deliberate assault.

There were 21 isolated ocular injuries (9 bilateral; 12 unilateral), 8 isolated skin injuries, 4 mixed eye and skin injuries, and 1 oral exposure. Involved chemicals were basic substances (11 cases), acidic substances (11 cases), an oxidizer (1 case), solvents (2 cases), and miscellaneous chemical substances (9 cases; acrylic coating, lacrimating agent, etc.).

Among the 25 isolated or mixed ocular injuries, the following signs and symptoms were noted: eye pain (18 cases), blepharospasm (4 cases; see Figure 3 for an example secondary to latex of Euphorbia lathyris exposure), conjunctival hyperemia (15 cases), palpebral edema (2 cases), excessive tearing (1 case), and blurred vision (7 cases). Among the 8 isolated skin injuries, there was 1 case with a deep
necrotic lesion and 7 cases of superficial lesions, erythema, or phlyctenae.

Only 1 case of an oral burn due to accidental ingestion of ammonia stored in an unlabeled bottle was noted. The patient immediately expectorated the ammonia. The tongue lesion before and after Diphoterine® rinsing repeated 5 times as a mouthwash and expectorated is shown in Figures 4 and 5.

Initial and final pain level assessment by VAS

The initial pain intensity ranged from 3 to 10 on the VAS. The initial median VAS score before Diphoterine® eye or skin flushing was 7 (IQR: 4-9). The final median VAS pain intensity score was 1 (IQR: 0-3). Thus, the difference between before-flushing and after-flushing with Diphoterine® was significant (Wilcoxon Rank Sum Test; p<0.0001).

The time interval between exposure and Diphoterine® solution eye and/or skin flushing ranged from 1-555 minutes (median: 77.5 minutes; IQR: 30-131 minutes).

Clinical signs and symptoms after diphoterine® eye and/or skin flushing

Ocular signs and symptoms: Resolution of eye pain in 14 cases (final VAS 0 or 1); marked decrease of eye pain in 7 cases (final VAS 2 or 3); persistence of moderate eye pain after Diphoterine® eye flushing in 3 cases related to chemical lesions induced by a reducing agent (aluminum-magnesium mixture; Case No. 6), “tear gas” (Case No. 18) and glyphosate soda (Case No. 28); Resolution of blepharospasm in the 4 observed cases (Cases Nos. 1, 5, 12, 28); Reduction of initial blurred vision in the 7 observed cases with regression or resolution of initial blurred vision (Cases Nos. 10, 11, 22, 26, 27, 30, 32); Resolution of initial palpebral edema in the 2 observed cases (Cases Nos. 1 and 9)

Cutaneous signs and symptoms: Resolution of all initial skin lesions in the 7 observed cases with superficial lesions (erythema or phlyctenae) by 48 hours post-exposure; In the 1 case of deep necrotic skin injury (Case No.4), there was no local improvement following Diphoterine® flushing. Recovery followed surgical excision and skin grafting. Of note, Diphoterine® flushing was quite delayed after exposure.

Oral signs and symptoms: In the only case of mouth exposure (to ammonia; Case No. 21), after 5 repeated Diphoterine® mouthwashes followed by expectoration (no swallowing), a reduction of the chemical...
injury was noted (Figures 4 and 5). On the following day, the patient was pain free and had no loss of taste sensation.

Results of ophthalmology specialist consultations: No lesions were noted in 12 patients; Six patients had minimal eye findings (moderate conjunctival lesions which resolved in a few days with standard eye drop treatment); One patient (Case No. 5) had a superficial ulceration of the cornea.

Discussion

It is generally accepted that decontamination of eye or skin chemical splashes should be done as soon as possible after exposure. While potable water as the flushing fluid has been utilized for a very long time, it is perhaps currently not the best option [1]. Diphosphine is a polyvalent amphoteric solution for flushing splashed chemicals off the skin or surface of the eyes. It has been used efficaciously for a number of years in industrial settings [2-5]. In the European Union, Diphosphine solution is a Class II medical device. It is not irritating to the eyes or skin, is not sensitizing in guinea pigs or humans, is non-toxic (rat oral/dermal LD₅₀ >2,000 mg/kg) and is not mutagenic in the Ames test [1,6].

Diphosphine solution has multiple methods of action

- As an aqueous solution, it flushes a large portion of the splashed chemical substance from the surface of the skin or eyes through mechanical entrainment and dilution;
- As an hypertonic solution, it limits penetration of the splashed chemical substance into the deep tissue layers of the skin or eyes by creating an osmotic pressure gradient;
- As an amphoteric solution (able to bind opposing chemical groups such as acids/bases or oxidizing/reducing agents), it halts the aggressive action of corrosive or irritant chemical substances.

Comparative studies have demonstrated the efficacy of Diphosphine solution. Gerard et al. [7] compared the action of Diphosphine solution and normal saline in vivo in the context of ammonium hydroxide eye injuries. These authors found a lack of stromal edema when Diphosphine solution was used and its presence when flushing was with normal saline. This finding is supported by the difference of osmotic pressure between the two flushing fluids (respectively ~800 mosmols/kg for Diphosphine solution versus 280 mosmols/kg for normal saline, while the osmotic pressure of the cornea is 420 mosmols/kg). As a biochemical rationale, the pH curve was decreased during flushing with Diphosphine solution.

In a 2002 review, Hall et al. [1] showed that Diphosphine solution was more efficacious than water in various industrial studies. Nehles et al. [4] found that when workplace corrosive substances eye and skin splashes were flushed with Diphosphine®, there was no need for medical treatment other than decontamination, and there were no sequelae and no lost work time.

Cavallini and Casati [8] and Cavallini et al. [9] investigated wound healing and concentrations of ß-endorphin, Substance P, and interleukin IL-6 in a rat in vivo study of concentrated hydrochloric acid skin injury flushed with either Diphosphine® solution, normal saline, or calcium gluconate solution. In the Diphosphine® group versus the normal saline and calcium gluconate solution groups, the following were observed:

- A more important decrease in lesion size in the Diphosphine® solution group;
- Significant beneficial changes in biological markers of pain in the Diphosphine® solution group: a significant decrease in Substance P concentration at 48 h (p<0.05) and a significant increase in ß-endorphin at 7 days (p<0.05);
- A significant decrease in inflammation as shown by decreased IL-6 concentrations at 48 h (p<0.05) and enhanced tissue repair.

Merle et al. [10,11] conducted a clinical study of 66 patients with deliberate assault eye splashes with a base chemical substance (ammonium hydroxide; Alkaline®) in Martinique. These authors reported that, compared to normal saline flushing, Diphosphine® solution was more efficacious for decreasing the time to corneal re-epithelization in patients with Roper-Hall scale Grade I and II lesions and seemed to be more suitable for emergent flushing of corrosive chemical substance exposed eyes. Schrage et al. [12] considered the pathophysiology of chemical ocular lesions and compared various eyewash solutions. Diphosphine® appeared to be the best option.

Ioannidis et al. [13] reported the case of a 76-year-old man with eye injury due to exposure to the latex of the Euphorbia lathyris plant. Despite flushing with 8 liters of normal saline followed by treatment with dexamethasone and cicatrizizing eye drops, the patient developed a corneal ulcer and severe pain which necessitated a 3-day hospitalization.

This clinical course is in sharp contract to Case No.1 reported here; a 59-year-old man who developed facial skin injuries, eye injuries, and severe pain 4 hours after handling the latex of this same plant. Euphorbia lathyris is a plant used by gardeners; in particular the cut stalks are inserted into mole burrows. The latex from the cut stalks has alkylating and base properties (pH=9) and also contains protease enzymes which repel moles.

After exposure at home, the patient took 10 mg of morphine (already in his possession for the treatment of fibromyalgia) and performed an eye wash with Dacroserum® solution which did not alleviate the pain. During the initial examination in the hospital emergency department, the patient had blepharospasm, facial lesions, and ocular pain which was scored as 8/10 on the VAS, a well as persistence of blepharospasm. Eye flushing with normal saline resulted in an increase in ocular pain (10/10 on the VAS). Flushing with Diphosphine® solution (250 mL for each eye) resulted in a decrease of ocular pain (6/10 on the VAS) and resolution of blepharospasm after 15 minutes (Figure 3). After 55 minutes, ocular pain had completely resolved. Ophthalmological examination a few hours later showed only a mild conjunctival lesion. As compared to the case reported by Ioannidis et al. [13], flushing with Diphosphine® solution resulted in a less severe lesion and rapid pain relief.

Donoghue [5] compared the efficacy of Diphosphine® solution with that of water for decontamination of alkaline chemical splashes in a clinical study involving 180 workers. In the group treated with Diphosphine® solution, there were no signs of lesions in 52.9% of cases versus 21.4% of cases flushed with water. Moreover, grade III and IV lesions were significantly less numerous in the Diphosphine® solution first group (7.9 vs. 23.8%; p<0.001).

Zack-Williams et al. [14] published a 2-year comparative evaluation study. There was a significant change in the wound pH pre- and post-flushing with Diphosphine® solution compared to water flushing (pH change of 1.076 versus 0.4; p<0.05). There were no significant differences in time to healing, length of hospital stay or need for
surgery. Based on the retrospective case series presented here, Diphoterine® solution could be valuable for flushing of corrosive and irritant chemical splashes in the hospital and pre-hospital settings.

Bverar [15] published a comparative study of CS “tear gas” exposures in Slovenian police officers flushed with Diphoterine® solution versus no flushing. The policemen refused to compare Diphoterine® solution with water flushing because of increased pain when CS exposures were flushed with water. Six policemen were exposed to CS only. A second group of 8 policemen sprayed their faces with Diphoterine® solution before CS exposure and a third group of 8 policemen sprayed their faces with Diphoterine® solution after exposure. The time between exiting the CS cloud and arriving at the “ready for action” checkpoint was measured. Facial pain both inside the CS cloud and at the checkpoint was assessed using a 0-10 visual analog scale (VAS).

The pain level inside the CS cloud was significantly lower in the group that pre-treated with Diphoterine® solution (5.6 ± 1.1; p=0.1) versus the CS only group (9.7 ± 0.5). In the post-CS-exposure treatment group, it was similar (9.1 ± 0.4). The time interval between CS exposure and arrival at the checkpoint was significantly shorter in the Diphoterine® solution pre-treatment group (1.26 ± 0.44 minutes) than in the CS only group (2.28 ± 0.25 minutes; p=0.04) and in the post-exposure treatment group (2.30 ± 0.48 minutes; p=0.02) where it was not different. The residual pain at the checkpoint in the Diphoterine® pre-CS-exposure (1.1 ± 0.4) and post-exposure (1.4 ± 0.7) groups was similar, with significantly less pain than in the CS only group (2.3 ± 0.5; p=0.02). In this study, post-CS-exposure decontamination with Diphoterine® solution reduced facial pain whereas pre-CS-exposure treatment reduced both pain and recovery time [15]. These findings are in substantial agreement with those reported in French gendarmes by Viala et al. [16].

Lynn et al. [17] published an independent systematic review of the safety and efficacy of Diphoterine® solution compared to water and normal saline for the decontamination of ocular and cutaneous chemical burns in humans. All studies published in peer-reviewed journals up to May 2016 were eligible for consideration. Such published data must have included Diphoterine® solution for decontamination of eye and/or skin chemical splashes as well as meeting other specified criteria. Acceptable studies had to use either a quantitative (e.g., number of lost workdays) or qualitative (e.g., level of erythema) approach when determining cutaneous and/or ocular lesion outcomes. These authors concluded that, despite a relatively small number of published studies, Diphoterine® solution is safe and highly efficacious in improving healing times, healing sequelae, and pain management of chemical skin and eye injuries in humans. Outcomes are significantly improved as compared to water or normal saline decontamination. These authors concluded:

“We recommend this product be readily available to emergency responders and companies that expose their employees to hazardous chemical substances in order to improve healing sequelae, pain management, and lost work days from these types of burns” [17].

Overall, Diphoterine® solution limits the action of the splashed chemical substance on the tissues. Through its physical actions, it removes the chemical substance in contact with the tissues (mechanical and osmotic actions). In addition, flushing with Diphoterine® solution enables the tissues to return to a physiologically acceptable pH. Lesion formation is thus halted. Since the tissue is no longer under aggression and in a physiologically acceptable environment, pain and inflammation decrease. The published studies reviewed show the same mechanisms, during and after flushing with Diphoterine® solution, as evidenced by decrease in pain and reduction of sequelae.

The majority of the cases reported here showed symptomatic improvement following Diphoterine® solution flushing. Absorption of the splashed chemical substance into the tissues and resultant cell damage are halted by effective flushing with Diphoterine® solution.

Conclusion

Eye and skin chemical lesions account for ~4% of all burn cases attending emergency departments. The context is often a domestic accident rather than an occupational exposure. The small number of chemical lesions resulting from occupational accidents observed in the hospital might be explained by the use of the polyvalent, amphoteric Diphoterine® solution as an emergency decontamination measure in workplace settings. Rapid use of Diphoterine® solution enables a reduction in the duration of tissue chemical exposure and hence a reduction in the lesions induced.

Both in vitro and in vivo, Diphoterine® solution has been shown to be effective on eye, skin and mucous membrane chemical injuries. For the best results, Diphoterine® solution flushing should begin as soon as possible after the chemical splash occurs in order to prevent or lessen lesion development. As more data are accumulated, the efficacy of Diphoterine® solution should become more apparent to pre-hospital responder organizations and emergency departments.

Conflict Delineations

AHH is a paid consultant to Laboratoire Prevor, Valmondois, France, manufacturer of Diphoterine®. All other authors report no conflicts of interest.

References


